Le centre hospitalier Bretagne Atlantique est un centre hospitalier du Morbihan, regroupant depuis 2000 deux hôpitaux, distants de 25 kilomètres : l'hôpital Prosper-Chubert à Vannes et l'hôpital Le Pratel à Auray.

During the past decade, CHBA Vannes conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHBA Vannes" #1 sponsor was "French Innovative Leukemia Organisation" with 2 trials, followed by "Intergroupe Francophone du Myelome" with 2 trials sponsored, "Centre Hospitalier Departemental Vendee" with 1 trials sponsored, "Gustave Roussy, Cancer Campus, Grand Paris" with 1 trials sponsored and "Institut Cancerologie de l'Ouest" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHBA Vannes" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "BeiGene" with 1 trials as a collaborator and "Bicetre Hospital" with 1 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "CHBA Vannes" are "Multiple Myeloma" (2 trials), "Breast Neoplasms" (1 trials), "CLL/SLL" (1 trials), "Catheter Dysfunction" (1 trials) and "HIV Infections" (1 trials). Many other conditions were trialed in "CHBA Vannes" in a lesser frequency.

Most popular intervention types in "CHBA Vannes" are "Drug" (4 trials), "Procedure" (3 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "ACA Continuation" (1 trials), "ASCT" (1 trials), "Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)" (1 trials), "Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab" (1 trials) and "Contrast agent injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHBA Vannes" are 9 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CHBA Vannes". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in CHBA Vannes, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHBA Vannes, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".